Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ThermoGenesis Holdings, Inc. THMO
$1.94
-$0.05 (-2.51%)
На 18:02, 12 мая 2023
-48.45%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3146230.00000000
-
week52high
22.95
-
week52low
1.79
-
Revenue
10483000
-
P/E TTM
0
-
Beta
2.53079500
-
EPS
-20.63000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 мая 2023 г. в 10:59
Описание компании
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 12 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 ноя 2020 г. |
| H.C. Wainwright | Buy | 17 апр 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 03 окт 2019 г. |
| H.C. Wainwright | Buy | Buy | 23 мая 2018 г. |
| HC Wainwright & Co. | Buy | 17 апр 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Xu Xiaochun | A | 12281091 | 10552234 | 28 июн 2022 г. |
| Cauble Jeffery | D | 0 | 40000 | 27 мая 2021 г. |
| Xu Xiaochun | D | 0 | 240000 | 27 мая 2021 г. |
| Xu Xiaochun | A | 240000 | 240000 | 04 июн 2020 г. |
| Westgate Mark | A | 10000 | 10000 | 04 июн 2020 г. |
| MEDFORD RUSSELL M | A | 10000 | 10000 | 04 июн 2020 г. |
| JOSEPH THOMIS | A | 10000 | 10000 | 04 июн 2020 г. |
| Cauble Jeffery | A | 40000 | 40000 | 04 июн 2020 г. |
| Donaghy Debra | A | 10000 | 10000 | 04 июн 2020 г. |
| Xu Xiaochun | D | 1728857 | 621637 | 28 апр 2020 г. |
Новостная лента
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 10:18
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to Review Financial and Operating Results for the Third Quarter Ended September 30, 2022.
ThermoGenesis Holdings, Inc. (THMO) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 20:18
ThermoGenesis Holdings, Inc. (THMO) delivered earnings and revenue surprises of -233.33% and 28.79%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2022 and Provide a Corporate Strategic Update
PRNewsWire
07 ноя 2022 г. в 13:20
Conference Call to be Held on November 10, 2022 RANCHO CORDOVA, Calif. , Nov. 7, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2022, and provide a corporate strategic update on Thursday, November 10, 2022.
ThermoGenesis Holdings, Inc. (THMO) CEO Dr. Chris Xu on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
13 авг 2022 г. в 15:31
ThermoGenesis Holdings, Inc. (NASDAQ:THMO ) Q2 2022 Results Conference Call August 11, 2022 3:00 PM ET Company Participants Paula Schwartz - Rx Communications Dr. Chris Xu - Chief Executive Officer Jeff Cauble - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright Operator Good day, and welcome to the ThermoGenesis Holdings Conference Call and Webcast to Review Financial and Operating Results for the Second Quarter Ended June 30, 2022.
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide a Corporate Strategic Update
PRNewsWire
09 авг 2022 г. в 13:43
Conference Call to be Held on August 11, 2022 RANCHO CORDOVA, Calif. , Aug. 9, 2022 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company will release its financial results for the second quarter ended June 30, 2022 and provide a corporate strategic update on Thursday, August 11, 2022.